| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03909295 Details | 2021-10-08 Interventional | 3 | 52 | Sacubitril and … Valsartan Heart Failure Heart Failure W… | This study was terminated early because the primary endpoint of PARAGON-HF was not met. - | |||
| NCT02647255 Details | 2021-10-08 Interventional | 2/3 | 10 | Methylprednisol… Methylprednisol… Methylprednisol… Prednisolone Prednisolone ac… Prednisolone he… Prednisolone ph… Acute Kidney In… Glomerulonephri… Glomerulonephri… Kidney Diseases Renal Insuffici… Acute Renal Ins… Rapidly Progres… | Due to the rarity and rapid progressive course of the disease, patients were less likely to
participate in randomization. - | |||
| NCT02576977 2015-002509-13 Details | 2021-10-08 Interventional | 3 | 251 | Dexamethasone Pembrolizumab Pomalidomide Multiple Myelom… Neoplasms, Plas… | The study was terminated early due to business reasons The MK-3475-183 study was stopped/terminated early. Endpoint statistics may be biased due to the incomplete treatment and follow-up of participants after study termination | |||
| NCT04252248 Details | 2021-10-06 Interventional | 1 | 3 | Decitabine Head and Neck N… Anogenital Canc… Head and Neck C… | Organizational reasons - | |||
| NCT04025177 Details | 2021-10-06 Interventional | 2 | 0 | Indomethacin Ductus Arterios… Premature Birth Patent Ductus A… | Halted due to feasibility issues - | |||
| NCT02298166 Details | 2021-10-06 Interventional | 3 | 9 | Crenolanib Cytarabine Mitoxantrone Leukemia Leukemia, Myelo… Leukemia, Myelo… Acute Myeloid L… | The manufacturer Arog Pharmaceuticals Inc has terminated the Agreement Concerning the Support
of an Investigator Initiated Trial this became valid on 2020/03/09 - | |||
| NCT01468311 Details | 2021-10-06 Interventional | 1/2 | 6 | Daclizumab Hodgkin Disease Lymphoma Hodgkin Lymphom… | Poor enrollment and ability to radioconjugate Daclizumab. Neither Center for Cancer Research
(CCR) or Nuclear Medicine/Radiology wanted to do the facilities upgrade and hire personnel
needed to radioconjugate the drug at the Clinical Center. - | |||
| NCT00615160 2005-002192-32 Details | 2021-10-06 Interventional | 1/2 | 9 | Dacarbazine Vatalanib Melanoma | Substance was withdrawn from further development. - | |||
| NCT04882163 2020-005333-32 Details | 2021-10-05 Interventional | 1/2 | 0 | Bendamustine Hy… Dexamethasone Gemcitabine Lenalidomide Polatuzumab ved… Rituximab Lymphoma Lymphoma, B-Cel… | Business objectives have changed - | |||
| NCT01496612 Details | 2021-10-05 Interventional | 2 | 9 | Buspirone Anxiety Disorde… Epilepsies, Par… Epilepsy Seizures Anxiety Disorde… Depression Partial Epileps… | - - | |||
| NCT04325698 Details | 2021-10-04 Interventional | 3 | 8 | Bevacizumab Carboplatin Paclitaxel Carcinoma, Non-… Advanced Non-sq… | The study was terminated as part of the decision by Pfizer to halt its biosimilars programs in
China. - | |||
| NCT03560011 2017-000826-36 Details | 2021-10-04 Interventional | 2/3 | - | Antibodies Immunoglobulins Immunoglobulins… Nephrosis Nephrotic Syndr… Syndrome Steroid-Depende… | Decision of Data Safety Monitoring Board - | |||
| NCT01549886 Details | 2021-10-04 Interventional | 2 | 5 | Rituximab Lymphoma Lymphoma, B-Cel… Lymphoma, Non-H… Non-Hodgkin's L… | Due to business reasons. - | |||
| NCT04614298 Details | 2021-09-30 Interventional | 4 | 0 | Brodalumab Psoriasis Moderate to Sev… | Due to the reconsideration of KHK4827's business in China, it. was decided to withdraw this
clinical trial prior to enrollment of first participant. - | |||
| NCT01170650 Details | 2021-09-30 Interventional | 3 | 441 | Doxorubicin Liposomal doxor… Carcinoma, Ovar… Ovarian Neoplas… Ovarian Cancer | DSMB decision - | |||
| NCT03607955 Details | 2021-09-29 Interventional | 1 | 0 | Carboplatin Paclitaxel Carcinoma, Ovar… Fallopian Tube … Epithelial Ovar… Fallopian Tube … Primary Periton… | Trial may move forward as an NCI-sponsored trial and not an investigator initiated trial. - | |||
| NCT03260972 Details | 2021-09-29 Interventional | 3 | 0 | Chloroprocaine Cesarean Sectio… Pain | Withdrawn by IRB - | |||
| NCT02833766 Details | 2021-09-29 Interventional | 2 | 48 | Doxorubicin Breast Neoplasm… Breast Cancer | the trial was prematurely terminated as per SAKK board decision from 14th of November 2020. The
trial is to be terminated after primary endpoint is reached. - | |||
| NCT02272868 Details | 2021-09-29 Interventional | 1/2 | 7 | Omeprazole Polyethylene gl… Rifaximin Crohn Disease Crohn's Disease | - - | |||
| NCT03224182 Details | 2021-09-28 Interventional | 3 | 118 | Apaziquone Urinary Bladder… Bladder Cancer | Suspended development The study was terminated as per Sponsor's decision. |